OVERVIEW
Our proprietary claims data, which we factor into both a Claims Index and Patient Index, indicates upside to 4Q19 in clinical sample volume. Compared to 3Q19 trends, there is less upside heading into 4Q19 earnings where company guidance calls for 48,000 tests for the year and an implied clinical test volume of 13,345 for the quarter. Sequentially the trend continues to ramp steadily even before the announcement of Medicare's final LCD covering advanced tumors which was announced a this afternoon. Going forward it will be useful to see the trend in non lung cancer testing according to the diagnosis code on the submitted claim.
Thomas Tobin
Managing Director
Twitter
LinkedIn
Emily Evans
Managing Director – Health Policy
Twitter
LinkedIn
